Monoclonal Antibody to Noggin (NOG) Homo sapiens (Human) Monoclonal antibody

SYM1; SYNS1; Synostoses(Multiple)Syndrome 1; Symphalangism 1(Proximal)

Add to Cart Distributors
Overview
Properties
  • SourceMonoclonal antibody preparation, Host Mouse
  • Ig Isotype IgG2b Kappa, Clone Number A7
  • PurificationProtein A + Protein G affinity chromatography
  • LabelNone
  • Immunogen RPC130Hu01-Recombinant Noggin (NOG)
  • Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
  • TraitsLiquid, Concentration 1mg/mL
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Monoclonal Antibody to Noggin (NOG) Packages (Simulation)
  • Monoclonal Antibody to Noggin (NOG) Packages (Simulation)
  • Monoclonal Antibody to Noggin (NOG) DAB staining on IHC-P; Sample: Human Glioma Tissue; Primary Ab: 30µg/ml Mouse Anti-Human NOG Antibody Second Ab: 2µg/mL HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
  • MAC130Hu22.jpg Figure. Western Blot; Sample: Recombinant NOG, Human.
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specifity

The antibody is a mouse monoclonal antibody raised against NOG. It has been selected for its ability to recognize NOG in immunohistochemical staining and western blotting.

Usage

Western blotting: 0.5-3µg/mL;
Immunohistochemistry: 5-30µg/mL;
Optimal working dilutions must be determined by end user.

Storage

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Giveaways

Citations

  • Imbalance between BMP2 and Noggin induces abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitisPubMed: 26413886
  • Imbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing SpondylitisPubmed:26413886
  • Oxygen-glucose deprivation preconditioning protects neurons against oxygen-glucose deprivation/reperfusion induced injury via bone morphogenetic protein-7 mediated ERK, p38 and Smad signalling pathways.Pubmed:26385023
  • The BMP2 variant L51P restores the osteogenic differentiation of human mesenchymal stromal cells in the presence of intervertebral disc cells.pubmed:28266688
  • mbalance Between Bone Morphogenetic Protein 2 and Noggin Induces Abnormal OsteogenicDifferentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis.pubmed:26413886
  • The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells.pubmed:28981962
  • Efficient in vitro delivery of Noggin siRNA enhances osteoblastogenesispubmed:29167826
  • Low‐intensity pulsed ultrasound promotes bone morphogenic protein 9‐induced osteogenesis and suppresses inhibitory effects of inflammatory cytokines on cellular …Pubmed: 31006911
  • Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatmentPubmed: 32160825
  • Effect of Simvastatin Use in Free Tissue Transfer: An Experimental Study in a Rat Epigastric Free Flap ModelPubmed: 31995818
  • Slow diffusion on the monolayer culture enhances auto/paracrine effects of Noggin in differentiation of human iPS cells induced by BMPPubmed:35005256

Recommend products